Check out today's Biostock interview for an exciting read on the upcoming year with Alligator Bioscience AB CEO Søren Bregenholt following this link 👉https://lnkd.in/dg8Bd-Dw
Om oss
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator´s technology platform comprises the proprietary technologies ALLIGATOR-GOLD® and FIND®. ALLIGATOR-GOLD® is a human antibody library containing more than 60 billion unique antibody fragments. FIND® (Fragment Induced Diversity) is a molecular evolution technology for optimization of antibodies and other proteins. Immunotherapy of cancer: The immune system protects the body from attacks by pathogenic microorganisms (e.g. viruses and bacteria) and by cancer cells. Cancer cells usually evade the immune system, for example by producing immunosuppressive substances. Thus, although tumors often contain a large number of immune cells that should be able to attack the cancer cells, they are unable to do so due to the immunosuppression caused by the tumor. With immunotherapy, the ability of the immune system to fight cancer cells is improved in an effective manner, and the defense mechanisms used by the tumor are blocked or weakened. In addition, immune cells capable of destroying the cancer cells will survive in the body and thus protect it from metastases that may arise after treatment has ended. This "vaccination effect" is unique for immunotherapy.
- Webbplats
-
https://www.alligatorbioscience.com
Extern länk för Alligator Bioscience AB
- Bransch
- Forskning inom bioteknik
- Företagsstorlek
- 11–50 anställda
- Huvudkontor
- Lund
- Typ
- Publikt aktiebolag
- Grundat
- 2001
- Specialistområden
- Immunotherapy of cancer, Immuno-oncology, CD40 och Combination therapy
Adresser
-
Primär
Medicon Village
Lund, SE
Anställda på Alligator Bioscience AB
Uppdateringar
-
Looking ahead to the next 5–10 years, what will be the key disruptors and/or what can be improved upon in the pharma industry? Check out the piece in The Medicine Maker for insights from Alligator Bioscience AB CEO Søren Bregenholt! 👉
-
Today is World Pancreatic Cancer Day. A Day to acknowledge all those lives affected by this disease. We thank all our employees for their dedication, and those supporting us in our efforts to develop meaningful therapies towards hard-to-treat cancers. Below some links for those who wish to make a donation on this very important day. #PanCANawareness Pancreatic Cancer Action Network https://pancan.org/ Hirshberg Foundation for Pancreatic Cancer Research https://pancreatic.org/ The Lustgarten Foundation https://lustgarten.org/ Pancreatic Cancer UK https://lnkd.in/exmK22v Pancreatic Cancer Europe https://lnkd.in/eKqBFfhN Palema https://palema.org/
-
The 39th Annual Meeting for Society for Immunotherapy of Cancer #SITC2024 is happening right now, and Alligator Bioscience AB is of course participating to present data and explore groundbreaking research and innovative therapies. 🐊 Some presentations coming up, that you shouldn't miss: 📅 Friday, November 8 🎤 Presenter: Dr. Thomas Marron 📝 Title: Preliminary results from a phase I dose escalation study of ALG.APV-527, a 5T4 x 4-1BB bispecific antibody, in patients with advanced solid tumors demonstrate favorable safety and biological activity 📅 Saturday, November 9 🎤 Presenter: Ida Uddbäck, Senior Scientist at Alligator Bioscience AB 📝 Title: ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEACAM5, induces myeloid and T-cell dependent anti-tumor activity and synergizes with PD-1 inhibition 📅 Saturday, November 9 🎤 Presenter: Dr. Karen Geboes 📝 Title: CD40 agonist mitazalimab combined with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated efficacy and correlative biomarkers from the OPTIMIZE-1 trial We look forward to sharing our latest findings and connecting with fellow researchers and professionals in the field of cancer immunotherapy. 🐊
-
Join us at #PEGSEurope to hear Alligator Bioscience AB's CSO, Peter Ellmark, discuss the latest advancements in multispecifics and combination therapy. An excellent opportunity to learn about our innovative approach with #ATOR4066! 📅 18:15, Wednesday, 6 November 📍 Advancing Multispecifics & Combination Therapy | Protein & Antibody Engineering Summit | 5-7 November 2024 🎤 Peter Ellmark, PhD, CSO, Alligator Bioscience AB 📝 "ATOR-4066: Translating Clinical Success into a Next-Generation CD40xCEACAM5 Agonistic Neo-X-Prime Bispecific Antibody" 🔗 For conference details, follow this link: https://lnkd.in/dCSfD7nw
-
#BIOEurope2024 is on! Check out the BiotechTV interview with Alligator Bioscience AB CEO Søren Bregenholt... 👉
𝐁𝐈𝐎-𝐄𝐮𝐫𝐨𝐩𝐞: Sweden's Alligator Bioscience AB is ready for P3 for its CD40 program in pancreatic cancer - the company is looking for a partner as its first choice to move it forward. CEO Søren Bregenholt describes this program, and why Alligator chose pancreatic cancer. Plus, he discusses CD40 x CEA(CAM5) and 4-1BB x 5T4 bispecifics the company is developing. Full video: https://lnkd.in/gM5hTQ78 BiotechTV's coverage of #BIOEurope 2024 is brought to you by Pareto Securities. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh
-
Psst! Alligator Bioscience AB will be out and about this final quarter of 2024. Follow the post link to check out today's PR for upcoming conference participation. 👉
Alligator Bioscience to Participate in Upcoming Scientific and Investor Conferences in Q4 2024
https://alligatorbioscience.se
-
🌟 Thrilled to be featured in the latest white paper from Drug Target Review! 🌟 This paper highlights groundbreaking advancements in antibody research, and Alligator Bioscience AB's CEO, Søren Bregenholt, shares insights on targeting CD40 with bispecific antibodies to outsmart tumors. As you know, this innovative approach, particularly with our monospecific CD40 antibody, #mitazalimab, shows promising results in treating pancreatic cancer by effectively addressing tumors’ immune evasion mechanisms. 🔬 Discover more about our pioneering work in cancer immunotherapy and how we are making strides in the fight against cancer.
Beyond the lab: antibodies
https://www.drugtargetreview.com
-
Out just now - 📄 Alligator Bioscience AB's Q3 report for 2024! Check out the corresponding PR here : https://lnkd.in/diExTyWP and don't miss our webinar today, at 3:00 pm CEST, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the report. 🔗 Register here to join the call: https://lnkd.in/d9-kmw-4
-
🌟 Exciting News! 🌟 Thrilled to announce that our abstract for the upcoming mitazalimab presentation at #SITC2024 (#592) has been selected among the Top 100 abstracts out of 1,383 submissions! 🎉 We see this recognition as an affirmation of the significance of our research and its potential impact on the treatment of mPDAC. Stay tuned for more updates as we continue to explore the promising results of the OPTIMIZE-1 trial. The poster, entitled “CD40 agonist mitazalimab combined with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated efficacy and correlative biomarkers from the OPTIMIZE-1 trial” will be presented at the upcoming SITC 2024 meeting in Houston, from November 6-10. #SITC2024 #CancerResearch #mPDAC #mitazalimab #Top100
SITC 2024 Abstract Titles and Publications
sitcancer.org
Liknande sidor
Finansiering
Senaste finansieringsrunda
Okänd serie7 426 017,00 US$